Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put KaloBios' financial performance into perspective.

NASDAQ: KBIO
$2.12 + 0.21
Oct 2, 2015 at 4:00 PM ET
Minimum 20 minutes delay.
Data provided by eSignal.

Press Releases View all »

Aug 10, 2015
KaloBios Reports Second Quarter Financial Results and Provides Clinical Update
Jul 29, 2015
KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia
Jul 29, 2015
KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement

Investor Events View all »

Jun 23, 2015 at 10:30 AM ET
JMP Securities Life Sciences Conference 2015
Feb 12, 2015 at 8:30 AM ET
Leerink Partners 2015 Global Healthcare Conference
Jan 6, 2015 at 1:30 PM PT
KaloBios CF Phase 2 Data Conference Call

Shareholder Tools

Search Investor Relations

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue